Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions
{{output}}
Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as an important therapeutic option for patients with homologous recombination repair (HRR)-deficient cancers, especially those with BRCA1/2 mutations. Since the initial US Food Administration approval ... ...
